| About AliquantumRx

AliquantumRx is a near-clinical infectious-disease company focused on a single, high-impact objective: eliminating liver-stage malaria relapse through a short-course, G6PD testing-independent therapy. The company is advancing Cethromycin HCl through a malaria-first development strategy designed to reach human proof-of-concept and Priority Review Voucher monetization.

What Makes Us Different

Focused Liver-Stage Malaria Execution

While Cethromycin HCl is chemically an antibiotic, AliquantumRx is not a traditional antibiotic company. The dormant malaria indication relies on short, exposure-bounded treatment courses. We do not pursue multiple parallel clinical programs. Development is intentionally sequenced to eliminate core biological risk in malaria first, with optional value expansion evaluated only after human proof-of-concept.

Leadership

Leadership Team

David Sullivan, MD
Co-Founder, Chief Scientific Officer, Chair of the Board
Physician-scientist and professor at the Johns Hopkins Bloomberg School of Public Health with more than 30 years of experience in malaria research and clinical infectious diseases.

Nikola Kaludov, PhD
Co-Founder, President, Board Member
Biotechnology scientist and entrepreneur with extensive experience in translational drug development, IP strategy, and capital-efficient execution through IND readiness and partnering.

Amy Tapper, PhD
CMC/Advisor
Chemist with over 20 years of experience in drug discovery and development, with deep expertise in CMC strategy for emerging biotech companies.

Fredric D. Abramson, PhD, JD
Legal Advisor, Board Member
Attorney with decades of experience in patents, trademarks, and intellectual property strategy.

Steen Nissen, MSc, MBA
Executive Director
Global business executive with experience across life sciences, energy, and international operations.

Photos are from PHIL/CDC

© AliquantumRX Inc. 2022. All Rights Reserved.